Perspective Therapeutics (NYSEAMERICAN:CATX) Issues Quarterly Earnings Results

Perspective Therapeutics (NYSEAMERICAN:CATX) issued its earnings results on Monday. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.03, FiscalAI reports. Perspective Therapeutics had a negative net margin of 17,982.69% and a negative return on equity of 42.33%. The business had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.09 million.

Perspective Therapeutics Stock Performance

Shares of CATX opened at $3.00 on Tuesday. The company has a 50 day moving average of $3.10 and a two-hundred day moving average of $3.93. Perspective Therapeutics has a twelve month low of $1.96 and a twelve month high of $6.16.

Institutional Trading of Perspective Therapeutics

Institutional investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. increased its stake in Perspective Therapeutics by 184.1% during the 3rd quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock valued at $29,000 after purchasing an additional 5,475 shares in the last quarter. Aigen Investment Management LP acquired a new stake in shares of Perspective Therapeutics during the fourth quarter worth $28,000. nVerses Capital LLC purchased a new stake in shares of Perspective Therapeutics during the fourth quarter valued at $31,000. Engineers Gate Manager LP acquired a new position in shares of Perspective Therapeutics in the 4th quarter valued at $35,000. Finally, Caitong International Asset Management Co. Ltd acquired a new position in shares of Perspective Therapeutics in the 4th quarter valued at $42,000. 54.66% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts recently issued reports on CATX shares. BTIG Research reiterated a “buy” rating on shares of Perspective Therapeutics in a report on Friday, July 24th. Wedbush reaffirmed an “outperform” rating and set a $11.00 target price on shares of Perspective Therapeutics in a research report on Tuesday, May 5th. Eight research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $12.62.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.